The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease

Experimental Gerontology

Volumn 42, Issue 1-2, 2007, Pages 10-21

  Cole, Greg M ^a,b   Frautschy, Sally A ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain aging; Insulin resistance; TZDs (thiazolidinediones)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID BETA PROTEIN; CYTOKINE; DOCOSAHEXAENOIC ACID; DREBRIN; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN SENSITIZING AGENT; INSULINASE; NEUROTROPHIC FACTOR; NORASTERRIQUINONE B1; OLIGOMER; OMEGA 3 FATTY ACID; PLACEBO; PROTEIN KINASE; PROTEIN KINASE B; ROSIGLITAZONE; SMALL MOLECULE TRANSPORT AGENT; SOMATOMEDIN C;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN; BRAIN FUNCTION; CLEARANCE; DENDRITIC SPINE; DRUG DOSE COMPARISON; EXERCISE; HORMONE ACTION; HUMAN; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LEARNING; MEMORY; NERVE CELL PLASTICITY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

AGED; AGING; ALZHEIMER DISEASE; BRAIN; HUMANS; INSULIN; INSULIN RESISTANCE; NEUROTROPHIN 3; SIGNAL TRANSDUCTION;

EID: 33845577779     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2006.08.009     Document Type: Article

References (109)

1. Aizenman Y., and De Vellis J. Brain neurons develop in a serum and glial free environment: effects of transferrin, insulin, insulin-like growth factor I and thyroid hormone on neuronal survival, growth and differentiation. Brain Res. 406 (1987) 32-42
2. Akbar M., Calderon F., Wen Z., and Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc. Natl. Acad. Sci. USA 102 (2005) 10858-10863
3. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.E., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
4. Alvarez A., Cacabelos R., Sanpedro C., Garcia-Fantini M., and Aleixandre M. Serum TNFα levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol. Aging (2006) [Epub ahead of print]
5. Bartke A. Long-lived Klotho mice: new insights into the roles of IGF-1 and insulin in aging. Trends Endocrinol. Metab. 17 (2006) 33-35
6. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid β-protein toxicity. Cell 77 (1994) 817-827
7. Bhat R.V., Budd Haeberlein S.L., and Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89 (2004) 1313-1317
8. Boda B., Alberi S., Nikonenko I., Node-Langlois R., Jourdain P., Moosmayer M., Parisi-Jourdain L., and Muller D. The mental retardation protein PAK3 contributes to synapse formation and plasticity in hippocampus. J. Neurosci. 24 (2004) 10816-10825
9. Bokoch G.M. Biology of the p21-activated kinases. Annu. Rev. Biochem. 72 (2003) 743-781
10. Bothmer J., Markerink M., and Jolles J. Phosphoinositide kinase activities in synaptosomes prepared from brains of patients with Alzheimer's disease and controls. Neurosci. Lett. 176 (1994) 169-172
11. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., Rostaing P., Triller A., Salem Jr. N., Ashe K.H., Frautschy S.A., and Cole G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
12. Calon F., Lim G.P., Morihara T., Yang F., Ubeda O., Salem N.J., Frautschy S.A., and G.M C. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci. 22 (2005) 617-626
13. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., and Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 8 (2002) 1390-1397
14. Carro E., Trejo J.L., Spuch C., Bohl D., Heard J.M., and Torres-Aleman I. Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease?. Neurobiol. Aging. 27 11 (2005) 1618-1631 Epub 2005 Nov 7
15. Carson M.J., Behringer R.R., Brinster R.L., and McMorris F.A. Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron 10 (1993) 729-740
16. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., and Klein W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42 (2003) 12749-12760
17. Chua B.T., Volbracht C., Tan K.O., Li R., Yu V.C., and Li P. Mitochondrial translocation of cofilin is an early step in apoptosis induction. Nat. Cell Biol. 5 (2003) 1083-1089 Epub 2003 Nov 1023
18. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of b-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARg agonists. J. Neurosci. 20 (2000) 558-567
19. Connor B., Young D., Yan Q., Faull R.L., Synek B., and Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Mol. Brain Res. 49 (1997) 71-81
20. Cook D.G., Leverenz J.B., McMillan P.J., Kulstad J.J., Ericksen S., Roth R.A., Schellenberg G.D., Jin L.W., Kovacina K.S., and Craft S. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 162 (2003) 313-319
21. Craft S., Zallen G., and Baker L.D. Glucose and memory in mild senile dementia of the Alzheimer type. J. Clin. Exp. Neuropsychol. 14 (1992) 253-267
22. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., and Porte Jr. D. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50 (1998) 164-168
23. Craft S., Asthana S., Cook D.G., Baker L.D., Cherrier M., Purganan K., Wait C., Petrova A., Latendresse S., Watson G.S., Newcomer J.W., Schellenberg G.D., and Krohn A.J. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28 (2003) 809-822
24. Delarue J., LeFoll C., Corporeau C., and Lucas D. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?. Reprod. Nutr. Dev. 44 (2004) 289-299
25. Dore S., Kar S., and Quiron R. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci. USA 94 (1997) 4772-4777
26. Eldar-Finkelman H., and Krebs E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc. Natl. Acad. Sci. USA 94 (1997) 9660-9664
27. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., and Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. USA 100 (2003) 4162-4167
28. Florent S., Malaplate-Armand C., Youssef I., Kriem B., Koziel V., Escanye M.C., Fifre A., Sponne I., Leininger-Muller B., Olivier J.L., Pillot T., and Oster T. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J. Neurochem. 96 (2006) 385-395
29. Gasparini L., and Xu H. Potential roles of insulin and IGF-1 in Alzheimer's disease. Trends Neurosci. 26 (2003) 404-406
30. Grace E.A., Rabiner C.A., and Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 114 (2002) 265-273
31. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., and O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93 (2005) 105-117
32. Guthrie K.M., Nguyen T., and Gall C.M. Insulin-like growth factor-1 mRNA is increased in deafferented hippocampus: spatiotemporal correspondence of a trophic event with axon sprouting. J. Comp. Neurol. 352 (1995) 147-160
33. Hafen E. Cancer, type 2 diabetes, and ageing: news from flies and worms. Swiss Med. Wkly. 134 (2004) 711-719
34. Harigaya Y., Shoji M., Shirao T., and Hirai S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J. Neurosci. Res. 43 (1996) 87-92
35. Hayashi K., Ishikawa R., Ye L.H., He X.L., Takata K., Kohama K., and Shirao T. Modulatory role of drebrin on the cytoskeleton within dendritic spines in the rat cerebral cortex. J. Neurosci. 16 (1996) 7161-7170
36. Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., and Saido T.C. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. Chem. 280 (2005) 15229-15237
37. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., Peng Y., Cambareri G., Rocher A., Mobbs C.V., Hof P.R., and Pasinetti G.M. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 18 (2004) 902-904
38. Holzenberger M., Kappeler L., and De Magalhaes Filho C. IGF-1 signaling and aging. Exp. Gerontol. 39 (2004) 1761-1764
39. Hsu H.Y., and Wen M.H. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J. Biol. Chem. 277 (2002) 22131-22139
40. Hu X., Roberts J.R., Apopa P.L., Kan Y.W., and Ma Q. Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. Mol. Cell. Biol. 26 (2006) 940-954
41. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., Hyman B.T., and Irizarry M.C. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62 (2004) 925-931
42. Jolles J., Bothmer J., Markerink M., and Ravid R. Phosphatidylinositol kinase is reduced in Alzheimer's disease. J. Neurochem. 58 (1992) 2326-2329
43. Kitamura Y., Kitamura T., Sakaue H., Maeda T., Ueno H., Nishio S., Ohno S., Osada S., Sakaue M., Ogawa W., and Kasuga M. Interaction of Nck-associated protein 1 with activated GTP-binding protein Rac. Biochem. J. 322 Pt 3 (1997) 873-878
44. Kwon T., Kwon D.Y., Chun J., Kim J.H., and Kang S.S. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J. Biol. Chem. 275 (2000) 423-428
45. Larson E.B., Wang L., Bowen J.D., McCormick W.C., Teri L., Crane P., and Kukull W. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann. Intern. Med. 144 (2006) 73-81
46. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M., Hersh L.B., Sapolsky R.M., Mirnics K., and Sisodia S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120 (2005) 701-713
47. Lee J.M., and Johnson J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J. Biochem. Mol. Biol. 37 (2004) 139-143
48. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., and Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405 (2000) 360-364
49. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O'Brien P.C., and Palumbo P.J. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann. N.Y. Acad. Sci. 826 (1997) 422-427
50. Li J., Lee J.M., Johnson D.A., and Johnson J.A. Antioxidant responsive element activation by quinones: antioxidant responsive element target genes, role of PI3 kinase in activation. Meth. Enzymol. 378 (2004) 238-258
51. Lim G.P., Calon F., Morihara T., Yang F., Teter B., Ubeda O., Salem Jr. N., Frautschy S.A., and Cole G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 25 (2005) 3032-3040
52. Liu X., Yao D.L., and Webster H. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Multiple Sclerosis 1 (1995) 2-9
53. Lizcano J.M., and Alessi D.R. The insulin signalling pathway. Curr. Biol. 12 (2002) R236-R238
54. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., Serhan C.N., and Bazan N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115 (2005) 2774-2783
55. Ma Q.-L., Lim G.P., Harris-White M.E., Yang F., Ambegaokar S.S., Ubeda O., Beech W., Zhao L., Hu S., Teter B., Kayed R., Glabe C.G., Frautschy S.A., and Cole G.M. Antibodies against β-amyloid rapidly neutralize A β oligomers and inhibit GSK-3 β activation and tau phosphorylation in vivo and in vitro. J. Neurosci. Res. 83 (2006) 374-384
56. Maclean C.H., Issa A.M., Newberry S.J., Mojica W.A., Morton S.C., Garland R.H., Hilton L.G., Traina S.B., and Shekelle P.G. Effects of omega-3 fatty acids on cognitive function with aging, dementia, and neurological diseases. Evid. Rep. Technol. Assess. (Summ) (2005) 1-3
57. Maclean C.H., Newberry S.J., Mojica W.A., Issa A., Khanna P., Lim Y.W., Morton S.C., Suttorp M., Tu W., Hilton L.G., Garland R.H., Traina S.B., and Shekelle P.G. Effects of omega-3 fatty acids on cancer. Evid. Rep. Technol. Assess (Summ) (2005) 1-4
58. Maher F.O., Martin D.S., and Lynch M.A. Increased IL-1beta in cortex of aged rats is accompanied by downregulation of ERK and PI-3 kinase. Neurobiol. Aging 25 (2004) 795-806
59. Meng J., Meng Y., Hanna A., Janus C., and Jia Z. Abnormal long-lasting synaptic plasticity and cognition in mice lacking the mental retardation gene Pak3. J. Neurosci. 25 (2005) 6641-6650
60. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Aggarwal N., Schneider J., and Wilson R.S. Dietary fats and the risk of incident Alzheimer disease. Arch. Neurol. 60 (2003) 194-200
61. Neeper S.A., Gómez-Pinilla F., Choi J., and Cotman C.W. Exercise and brain neurotrophins. Nature 373 (1995) 109
62. Newman J., Rissman R.A., Sarsoza F., Kim R.C., Dick M., Bennett D.A., Cotman C.W., Rohn T.T., and Head E. Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol. (Berl) 110 (2005) 135-144
63. Nishijima C., Kimoto K., and Arakawa Y. Survival activity of troglitazone in rat motoneurones. J. Neurochem. 76 (2001) 383-390
64. Odetti P., Piccini A., Giliberto L., Borghi R., Natale A., Monacelli F., Marchese M., Assini A., Colucci M., Cammarata S., and Tabaton M. Plasma levels of insulin and amyloid beta 42 are correlated in patients with amnestic Mild Cognitive Impairment. J. Alzheimers. Dis. 8 (2005) 243-245
65. Olson D.E., and Norris S.L. Diabetes in older adults. Overview of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics 59 (2004) 18-24 quiz 25
66. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., and Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 39 (1996) 1392-1397
67. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., and Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53 (1999) 1937-1942
68. Papakonstanti E.A., and Stournaras C. Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol. Biol. Cell 13 (2002) 2946-2962
69. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., and Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199 (2006) 265-273
70. Peila R., Rodriguez B.L., and Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51 (2002) 1256-1262
71. Peraldi P., Xu M., and Spiegelman B.M. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest. 100 (1997) 1863-1869
72. Pezet S., and Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin. Ther. Targets 8 (2004) 391-399
73. Phiel C.J., Wilson C.A., Lee V.M., and Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 (2003) 435-439
74. Puskas L.G., Kitajka K., Nyakas C., Barcelo-Coblijn G., and Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc. Natl. Acad. Sci. USA 100 4 (2003) 1580-1585 E pub 2003 Feb 3
75. Rice D.P., Fox P.J., Max W., Webber P.A., Lindeman D.A., Hauck W.W., and Segura E. The economic burden of Alzheimer's disease care. Health Aff. (Millwood) 12 (1993) 164-176
76. Rickle A., Bogdanovic N., Volkman I., Winblad B., Ravid R., and Cowburn R.F. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15 (2004) 955-959
77. Rickle A., Bogdanovic N., Volkmann I., Zhou X., Pei J.J., Winblad B., and Cowburn R.F. PTEN levels in Alzheimer's disease medial temporal cortex. Neurochem. Int. 48 (2006) 114-123
78. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., and Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. (2006)
79. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., and de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimer's Dis. 8 (2005) 247-268
80. Salituro G.M., Pelaez F., and Zhang B.B. Discovery of a small molecule insulin receptor activator. Recent Prog. Horm. Res. 56 (2001) 107-126
81. Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003) 9796-9804
82. Schubert M., Gautam D., Surjo D., Ueki K., Baudler S., Schubert D., Kondo T., Alber J., Galldiks N., Kustermann E., Arndt S., Jacobs A.H., Krone W., Kahn C.R., and Bruning J.C. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 101 (2004) 3100-3105
83. Schwartz A.J., Brasel J.A., Hintz R.L., Mohan S., and Cooper D.M. Acute effect of brief low- and high-intensity exercise on circulating insuling like growth factor (IGF) 1, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J. Clin. Endocrinol. Metab. 81 (1996) 3492-3497
84. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T., Hayakawa T., Nunomura A., Chiba S., Perry G., Smith M., and Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273 (2000) 5-9
85. Shirao T., and Obata K. Two acidic proteins associated with brain development in chick embryo. J. Neurochem. 44 (1985) 1210-1216
86. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., and de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimer's Dis. 7 (2005) 63-80
87. Stein T.D., and Johnson J.A. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J. Neurosci. 22 (2002) 7380-7388
88. Stein T.D., Anders N.J., DeCarli C., Chan S.L., Mattson M.P., and Johnson J.A. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in τ phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J. Neurosci. 24 (2004) 7707-7717
89. Stevens J., and Killeen M. A randomised controlled trial testing the impact of exercise on cognitive symptoms and disability of residents with dementia. Contemp. Nurse 21 (2006) 32-40
90. Stocker H., Andjelkovic M., Oldham S., Laffargue M., Wymann M.P., Hemmings B.A., and Hafen E. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295 (2002) 2088-2091
91. Takashima A., Noguchi K., Sato K., Hoshino T., and Imahori K. tau protein kinase I is essential for amyloid β-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 90 (1993) 7789-7793
92. Taouis M., Dagou C., Ster C., Durand G., Pinault M., and Delarue J. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle. Am. J. Physiol. Endocrinol. Metab. 282 (2002) E664-E671
93. Toda M., Shirao T., and Uyemura K. Suppression of an actin-binding protein, drebrin, by antisense transfection attenuates neurite outgrowth in neuroblastoma B104 cells. Brain Res. Dev. Brain Res. 114 (1999) 193-200
94. Tong L., Balazs R., Thornton P.L., and Cotman C.W. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24 (2004) 6799-6809
95. Uchida Y., Ihara Y., and Tomonaga M. Alzheimer's disease brain extract stimulates the survival of cerebral cortical neurons from neonatal rats. Biochem. Biophys. Res. Commun. 150 (1988) 1263-1267
96. Vekrellis K., Ye Z., Qiu W.Q., Walsh D., Hartley D., Chesneau V., Rosner M.R., and Selkoe D.J. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci. 20 (2000) 1657-1665
97. Wang T., Qin L., Liu B., Liu Y., Wilson B., Eling T.E., Langenbach R., Taniura S., and Hong J.S. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J. Neurochem. 88 (2004) 939-947
98. Watson G.S., and Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17 (2003) 27-45
99. Watson G.S., Peskind E.R., Asthana S., Purganan K., Wait C., Chapman D., Schwartz M.W., Plymate S., and Craft S. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60 (2003) 1899-1903
100. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958
101. Webster N.J., Park K., and Pirrung M.C. Signaling effects of demethylasterriquinone B1, a selective insulin receptor modulator. Chembiochem 4 (2003) 379-385
102. Wei W., Wang X., and Kusiak J.W. Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. J. Biol. Chem. 277 (2002) 17649-17656 Epub 12002 Mar 17646
103. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., and Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23 (2003) 7504-7509
104. Yang E., Kim H., Lee J., Shin J.S., Yoon H., Kim S.J., and Choi I.H. Overexpression of LIM kinase 1 renders resistance to apoptosis in PC12 cells by inhibition of caspase activation. Cell. Mol. Neurobiol. 24 (2004) 181-192
105. Yuan Z.Q., Kim D., Kaneko S., Sussman M., Bokoch G.M., Kruh G.D., Nicosia S.V., Testa J.R., and Cheng J.Q. ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival. J. Biol. Chem. 280 (2005) 21483-21490
106. Zhao L., Teter B., Morihara T., Lim G.P., Ambegaokar S.S., Ubeda O.J., Frautschy S.A., and Cole G.M. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J. Neurosci. 24 (2004) 11120-11126
107. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., Weisbart R.H., Teter B., Frautschy S.A., and Cole G.M. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 9 (2006) 234-242
108. Zhou G.L., Zhuo Y., King C.C., Fryer B.H., Bokoch G.M., and Field J. Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration. Mol. Cell. Biol. 23 (2003) 8058-8069
109. Zubenko G.S., Stiffler J.S., Hughes H.B., and Martinez A.J. Reductions in brain phosphatidylinositol kinase activities in Alzheimer's disease. Biol. Psychiatry 45 (1999) 731-736